Vantage ESC 2019 roundup

A collection of all of Vantage's coverage from the 2019 European Society of Cardiology meeting.

Amarin hopes for guideline boost despite regulatory delay

3 September

Amarin is plugging a change in ESC guidelines to include Vascepa, but with the product’s regulatory fate undecided how much difference will this make to sales?

 

Carmat is stout-hearted in the face of a challenging schedule

3 September

Carmat says its artificial heart is the best such device in existence. But time is short, and so is money.

 

Medicines Company impresses with inclisiran

2 September

With decent efficacy and clean safety in the Orion-11 trial, questions now turn to pricing and whether The Medicines Company will be taken out.

 

Trial failure leaves Cellaegis in limbo

1 September

Before today’s trial readout no one was sure how remote ischaemic conditioning worked; now the investigators are pretty certain that it doesn’t.

 

Astra’s latest Brilinta hopes bleed out on full Themis data

1 September

An increased risk of bleeding outweighs Brilinta’s benefits in a primary prevention population, but there might be a way forward in a patient subgroup.

 

Novartis sees reasons to push on post-Paragon

1 September

With a narrow primary endpoint miss and a 15% decrease in hospitalisations, Novartis is adamant that Entresto can get approved in HFpEF.

 

Farxiga looks DAPA outside diabetes

1 September

With strong data in hand Astrazeneca now needs to get cardiologists on board, and stay ahead of Lilly and Boehringer.

 

ESC preview – Medicines Company hopes for a starring role

19 August

Novartis has been reduced to a Paragon data dredge, but results with The Medicines Company’s inclisiran, Astrazeneca’s Brilinta and Cellaegis’ AutoRIC device should pique interest.

Related Topics

Share This Article